Sign In
Buy COR
$306.28
-2.09 (-0.678%)
At Close: Aug 04, 2026
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Wednesday, 06'th Aug 2025
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Cencora (COR) Q3 Earnings and Revenues Surpass Estimates
08:41am, Wednesday, 06'th Aug 2025
Cencora (COR) came out with quarterly earnings of $4 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.34 per share a year ago.
Cencora raises annual profit forecast on strong demand for specialty drugs
07:51am, Wednesday, 06'th Aug 2025
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl
Cencora Reports Fiscal 2025 Third Quarter Results
06:30am, Wednesday, 06'th Aug 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
01:11pm, Monday, 04'th Aug 2025
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
Gear Up for Cencora (COR) Q3 Earnings: Wall Street Estimates for Key Metrics
10:16am, Friday, 01'st Aug 2025
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:08am, Wednesday, 30'th Jul 2025
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
08:32am, Tuesday, 15'th Jul 2025
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J. , July 15, 2025 /PRN
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Friday, 11'th Jul 2025
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
09:06am, Friday, 11'th Jul 2025
COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
07:30am, Thursday, 03'rd Jul 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the openi
VANCOUVER, BC / ACCESS Newswire / June 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce high‐grade copper channel results from the
Nittetsu Mining Provides $1.5 Million Fifth Earn-in Payment for Camino's Los Chapitos Project
06:00am, Thursday, 05'th Jun 2025
VANCOUVER, BC / ACCESS Newswire / June 5, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of CAD$1.5 million from explorati
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
10:46am, Monday, 02'nd Jun 2025
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
10:36am, Friday, 30'th May 2025
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
